Pharma in Focus & Mercurial reports on some interesting trends among the top 20 PBS products for the quarter of September 30. Figures released by the PBS show that Humira’s (adalimumab) dominance continues, while Eylea (afibercept) and Lucentis (ranibizumab) are neck and neck in second and third spot respectively. For more on this article click here.
Analytics for this pharma in focus story was generated using MiPortal, Mercurial’s cloud-based business intelligence & analytics platform. Click here for a free trial or contact Regan McCracken – Director – Commercial Effectiveness, on 02 8705 8754.
About Pharma in Focus
Pharma in Focus (PIF) is Australia’s premier independent pharma industry news service.